NYSE:AIM

AIM ImmunoTech (AIM) Stock Forecast, Price & News

$0.44

0.00 (0.00%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.43
▼
$0.46
50-Day Range: $0.40
▼
$0.54
52-Week Range: $0.29
▼
$1.05

Volume: 82,152 shs
Average Volume: 64,258 shs
Market Capitalization: $21.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About AIM ImmunoTech (NYSE:AIM) Stock

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Stock News Headlines

May 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and AIM ImmunoTech (AIM)

May 15, 2023 | msn.com

AIM ImmunoTech Q1 2023 Earnings Preview

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 15, 2023 | msn.com

Earnings Preview: AIM ImmunoTech

May 15, 2023 | finance.yahoo.com

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

May 15, 2023 | americanbankingnews.com

AIM ImmunoTech (AIM) Scheduled to Post Earnings on Tuesday

May 9, 2023 | finance.yahoo.com

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

April 22, 2023 | americanbankingnews.com

Analyzing Palisade Bio (NASDAQ:PALI) & AIM ImmunoTech (NYSE:AIM)

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

April 12, 2023 | finance.yahoo.com

AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE

April 12, 2023 | finance.yahoo.com

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

April 10, 2023 | finance.yahoo.com

AIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD

April 9, 2023 | finance.yahoo.com

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2022 Earnings Call Transcript

April 7, 2023 | markets.businessinsider.com

Ascendiant Remains a Buy on AIM ImmunoTech (AIM)

April 5, 2023 | finanznachrichten.de

AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

April 5, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for AIM ImmunoTech (AIM)

March 30, 2023 | tmcnet.com

AIM ImmunoTech Bolsters Board of Directors with Appointment

March 30, 2023 | msn.com

AIM ImmunoTech Earnings Preview

March 27, 2023 | finance.yahoo.com

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

March 26, 2023 | americanbankingnews.com

AIM ImmunoTech (NYSE:AIM) Trading Down 4.2%

March 17, 2023 | baystreet.ca

Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer

March 16, 2023 | tmcnet.com

AIM ImmunoTech Announces Late-Breaking Presentation at the

March 16, 2023 | finance.yahoo.com

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

March 8, 2023 | tmcnet.com

AIM ImmunoTech Announces Publication of New Analysis of

March 6, 2023 | finanznachrichten.de

AIM ImmunoTech Inc.: AIM ImmunoTech Issues Letter to Stockholders

February 28, 2023 | finance.yahoo.com

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

February 17, 2023 | tmcnet.com

AIM ImmunoTech to Participate in Solve M.E.

See More Headlines

AIM Price History

30 days | 90 days | 365 days | Advanced Chart

AIM Company Calendar

Last Earnings: 4/03/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:AIM
CUSIP: N/A
CIK: 946644
Web: aimimmuno.com
Phone: (352) 448-7797
Fax: 215-988-1739
Employees: 21
Year Founded: 1990

Profitability

EPS (Most Recent Fiscal Year): ($0.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,440,000.00
Net Margins: -12,362.82%
Pretax Margin: -12,362.82%
Return on Equity: -47.58%
Return on Assets: -44.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.05
Quick Ratio: 18.05

Sales & Book Value

Annual Sales: $157,000.00
Price / Sales: 137.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 48,408,000
Free Float: 48,398,000
Market Cap: $21.54 million
Optionable: Not Optionable
Beta: -0.30

Social Links

Key Executives

Thomas Kenwood Equels
Executive Vice Chairman, President & CEO

Peter W. Rodino
COO, Secretary & General Counsel

Robert Dickey
Chief Financial Officer

David R. Strayer
Chief Medical Officer

Christopher McAleer
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AIM Stock - Frequently Asked Questions

How have AIM shares performed in 2023?: AIM ImmunoTech's stock was trading at $0.3119 at the beginning of the year. Since then, AIM stock has increased by 42.7% and is now trading at $0.4450.
View the best growth stocks for 2023 here.
When is AIM ImmunoTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our AIM earnings forecast.
How were AIM ImmunoTech's earnings last quarter?: AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings data on Monday, April, 3rd. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter. AIM ImmunoTech had a negative net margin of 12,362.82% and a negative trailing twelve-month return on equity of 47.58%.
What other stocks do shareholders of AIM ImmunoTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?: AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."
Who are AIM ImmunoTech's major shareholders?: AIM ImmunoTech's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Insiders that own company stock include Stewart Appelrouth, Thomas K Equels and Thomas K Equels.
View institutional ownership trends.
How do I buy shares of AIM ImmunoTech?: Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AIM ImmunoTech's stock price today?: One share of AIM stock can currently be purchased for approximately $0.45.
How much money does AIM ImmunoTech make?: AIM ImmunoTech (NYSE:AIM) has a market capitalization of $21.54 million and generates $157,000.00 in revenue each year. The company earns $-19,440,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.
How can I contact AIM ImmunoTech?: AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for the company is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739.

This page (NYSE:AIM) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial